Skip to content
  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
PHP Toggle Menu

Category: Publication

Randomized phase I trial of adjuvant individualized TG4050 vaccine in patients with locally advanced resected HPV-negative head and neck squamous cell carcinoma (HNSCC)

C. Le Tourneau, et al. SITC 2024  Abstract available on the SITC website – Download the abstract and the poster

Published 7 November 2024
Categorized as 2024, Myvac, Publication, publication key en, TG4050

TG7010: a Novel Chimeric Oncolytic Poxvirus Encoding IL-12 with Improved Properties for Systemic Delivery

J. Foloppe, et al. IOVC 2024  Abstract available on the IOVC website – Download the abstract and the poster

Published 27 October 2024
Categorized as -others, 2024, Invir.IO, Publication

Oncolytic viruses alter the biogenesis of tumor extracellular vesicles and influence their immunogenicity

U. Hirigoyen, et al. Oncology 2024 Article available on the Molecular Therapy Oncology website – Download the Article

Published 24 September 2024
Categorized as -others, 2024, Invir.IO, Publication

Initial clinical results of BT-001, an oncolytic virus expressing an anti-CTLA4 mAb, administered as single agent and in combination with pembrolizumab in patients with advanced solid tumors

S. Champiat, et al. ESMO 2024  Abstract available on the ESMO website – Download the abstract and the poster

Published 14 September 2024
Categorized as 2024, BT-001, Publication

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvionment

L.Fend, et al. ESMO 2024  Abstract available on the CICON website – Download the abstract and the poster

Published 10 September 2024
Categorized as 2024, Invir.IO, Publication, TG6050-en

TG6050, an oncolytic vaccinia virus encoding interleukin-12 and anti-CTLA-4 antibody, favors tumor regression via profound immune remodeling of the tumor microenvironment

F. Azar et al. Journal for ImmunoTherapy of Cancer July 2024 Article available on JITC website

Published 27 August 2024
Categorized as 2024, Publication, TG6050-en

Personalized vaccine TG4050 induces polyepitopic immune responses against private neoantigens in resected HPV negative head and neck cancers

A. Lalanne, et al. AACR 2024  Abstract available on the AACR website – Download the poster Poster Presentation

Published 9 April 2024
Categorized as 2024, Myvac, Publication, TG4050

Phase Ib/II trial of tipapkinogene sovacivec (TG4001), a therapeutic human papillomavirus 16-vaccine, in combination with avelumab in patients with advanced human papillomavirus 16-positive cancers

C. Le Tourneau, et al.European Journal of Cancer, July 2023 (191)Access the article herePublication

Published 29 August 2023
Categorized as -others, 2023, Publication, TG4001, TG4001

Safety and Immunogenicity of TG4050; a personalized cancer vaccine in head and neck carcinoma

C. Ottensmeier, et al. ASCO 2023  Abstract available on the ASCO website – Download the abstract and the posterPoster Presentation

Published 26 May 2023
Categorized as 2023, Myvac, Publication, TG4050

Immunogenicity and clinical activity of Tipapkinogen sovacivec (TG4001), an HPV-16 cancer vaccine: a randomized phase 2 study in recurrent or metastatic (R/M) anogenital cancers

C. Le Tourneau, et al. ESMO 2023 Abstract available on the ESMO website – Download the abstract – Download the poster

Published 25 May 2023
Categorized as 2023, Publication, TG4001, TG4001

Posts pagination

Newer posts Page 1 … Page 3 … Page 13 Older posts
Get to know us

About us

myvac

Pipeline

Investors

Partnering

Company

Career

ESG

Suppliers

Contacts

Legal documents

Legal notices

Privacy Policy

Ethics and compliance

Cookie policy

  • About us
    • About us
    • Executive commitee
    • Board of Directors
    • Scientific advisors
    • Corporate governance
    • ESG
  • myvac
    • myvac – individualized therapeutic vaccines
  • Pipeline
    • Pipeline
    • TG4050
    • TG4070
    • BT-001
    • TG6050
    • Publications and Presentations
    • Clinical trials FAQ
  • Investors
    • Investor Presentation & Contacts
    • Press releases & events
    • Financial Information
    • Stock Information
    • Annual General Meeting
  • Career
  • English
  • French
Menu